Celldex Therapeutics Price to Book Ratio 2010-2022 | CLDX

Historical price to book ratio values for Celldex Therapeutics (CLDX) over the last 10 years. The current price to book ratio for Celldex Therapeutics as of March 23, 2023 is 5.24.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Celldex Therapeutics Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2023-03-24 36.56 5.29
2022-12-31 44.57 $6.91 6.45
2022-09-30 28.11 $7.33 3.83
2022-06-30 26.96 $7.98 3.38
2022-03-31 34.06 $8.51 4.00
2021-12-31 38.64 $8.98 4.30
2021-09-30 53.99 $9.36 5.77
2021-06-30 33.44 $4.60 7.27
2021-03-31 20.60 $4.90 4.20
2020-12-31 17.52 $5.29 3.31
2020-09-30 14.83 $5.81 2.55
2020-06-30 13.00 $6.10 2.13
2020-03-31 1.66 $4.72 0.35
2019-12-31 2.23 $5.54 0.40
2019-09-30 2.13 $6.37 0.33
2019-06-30 2.68 $7.40 0.36
2019-03-31 4.92 $8.77 0.56
2018-12-31 2.97 $10.37 0.29
2018-09-30 6.77 $11.40 0.59
2018-06-30 7.55 $12.26 0.62
2018-03-31 34.95 $14.02 2.49
2017-12-31 42.60 $25.59 1.66
2017-09-30 42.90 $24.87 1.72
2017-06-30 37.05 $27.24 1.36
2017-03-31 54.15 $29.92 1.81
2016-12-31 53.10 $33.02 1.61
2016-09-30 60.60 $32.15 1.89
2016-06-30 65.85 $35.40 1.86
2016-03-31 56.70 $39.49 1.44
2015-12-31 235.20 $44.07 5.34
2015-09-30 158.10 $48.43 3.26
2015-06-30 378.30 $52.62 7.19
2015-03-31 418.05 $57.17 7.31
2014-12-31 273.75 $35.42 7.73
2014-09-30 194.40 $40.13 4.84
2014-06-30 244.80 $44.50 5.50
2014-03-31 265.05 $48.97 5.41
2013-12-31 363.15 $53.72 6.76
2013-09-30 531.45 $28.97 18.34
2013-06-30 234.15 $32.79 7.14
2013-03-31 173.70 $36.14 4.81
2012-12-31 100.65 $22.31 4.51
2012-09-30 94.50 $22.44 4.21
2012-06-30 77.63 $24.13 3.22
2012-03-31 76.35 $27.54 2.77
2011-12-31 39.00 $23.30 1.67
2011-09-30 34.28 $27.40 1.25
2011-06-30 53.25 $31.25 1.70
2011-03-31 60.30 $30.77 1.96
2010-12-31 61.80 $35.20 1.76
2010-09-30 60.00 $24.33 2.47
2010-06-30 68.40 $28.21 2.42
2010-03-31 92.10 $32.32 2.85
2009-12-31 70.05 $34.90 2.01
2009-09-30 82.35 $-2.11 -38.94
2009-06-30 117.30 $4.06 28.87
2009-03-31 97.65 $11.17 8.74
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.714B $0.002B
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.122B 8.73
GSK (GSK) United Kingdom $75.233B 9.43
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.461B 19.38
Ginkgo Bioworks Holdings (DNA) United States $2.529B 0.00
Arcus Biosciences (RCUS) United States $1.165B 0.00
Biohaven (BHVN) United States $0.882B 0.00
Emergent Biosolutions (EBS) United States $0.391B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.153B 0.00
Enzo Biochem (ENZ) United States $0.102B 0.00
SQZ Biotechnologies (SQZ) United States $0.018B 0.00
Gelesis Holdings (GLS) United States $0.011B 0.00